LIXTE Biotechnology Joins Russell Microcap Index, Boosting Visibility Among Institutional Investors

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) announced it has been added to the Russell Microcap Index, effective after the close of U.S. markets on June 26, 2026, with the reconstituted index taking effect at the opening of trading on June 29, 2026. Inclusion in this widely followed benchmark is expected to enhance the company’s visibility among institutional investors and investment products that track Russell indexes, according to the company’s press release.

The milestone reflects progress under LIXTE’s new leadership and strategic direction, supporting its efforts to build a platform focused on AI energy infrastructure equipment and services. The Russell Microcap Index is reconstituted annually and measures the performance of smaller publicly traded U.S. companies.

LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company focused on new targets for cancer drug development and developing and commercializing cancer therapies. The company has demonstrated that LB-100, its lead compound and first-in-class lead clinical PP2A inhibitor, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma.

Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. Additional information about Liora Technologies can be found at www.lioratechnologies.com.

Being added to the Russell Microcap Index marks a notable achievement for LIXTE, providing the company with greater credibility and potential for increased trading liquidity. Index inclusion often leads to automatic buying by funds that track the index, which can stabilize and boost the stock price. For a company like LIXTE, which is navigating clinical trials and developing new technologies, this enhanced visibility could attract more institutional interest and support future capital-raising efforts.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is LIXTE Biotechnology Joins Russell Microcap Index, Boosting Visibility Among Institutional Investors.

The post LIXTE Biotechnology Joins Russell Microcap Index, Boosting Visibility Among Institutional Investors appeared first on citybuzz.